Visit LabLeaders.com for more information about programs designed to provide laboratory professionals with clinical and strategic insights, support, and solutions from the top innovators in the laboratory industry.
Recently, the FDA announced the decision to reclassify rapid antigen-based influenza diagnostics. What does this mean for your lab and who will be affected?"
Join AACC and LabLeaders as Dr. Rick Nolte, Professor and Medical Director at the Medical University of South Carolina, shares his expert insights on the FDA’s reclassification of this rapid flu test, and why it's an opportunity for lab leadership.
Rick Nolte, Ph.D., D(ABMM), F(AAM)
Professor and Vice Chair for Laboratory Medicine, Department of Pathology and Laboratory Medicine Medical Director for Clinical Laboratories, Molecular Pathology Laboratory, and Point-Care-Testing Medical University of South Carolina
This webinar will enable you to:
- Explain the what and why behind the FDA reclassification of rapid antigen flu testing
- Communicate who will likely be impacted by the reclassification and the associated lab leadership opportunity
- Describe advances in flu testing technology and what to consider if planning to switch flu testing methods
This webinar is intended for laboratory professionals, physicians and pathologists; hospital administrators; and other professionals working in the clinical laboratory testing industry.